| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04352166 Details | 2024-02-02 Interventional | 2 | - | Buprenorphine Opioid-Related … Substance-Relat… Opioid-use Diso… | U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research
that included a pause of human subjects research as of June 23, 2023. This study will resume
recruitment after OHRP has approved the resumption of research. - | |||
| NCT04327934 Details | 2024-02-02 Interventional | 1 | 28 | Ganirelix Methyltestoster… Prolactin Relea… Testosterone Testosterone 17… Testosterone en… Testosterone un… Hypertension Polycystic Ovar… Syndrome | Unble to complete all arms of the planned study due to Covid stoppage and difficulty with
recruiting and getting enrolled participants to return post Covid. Our primary limitation was stoppage due to Covid (our laboratory was forced to close). We also had a very challenging time recruiting subjects when we reopened after the three-month closure under new rules. Subjects who had been enrolled did not return, and new subjects were difficult to recruit. Thus, we were not able to complete all arms of the planned study. We were able to answer our primary questions regarding autonomic function in women with PCOS. | |||
| NCT04299373 Details | 2024-02-02 Interventional | 1 | 3 | Ethanol Bariatric Surge… | In an effort to seek a more suitable method to measure alcohol clearance. - | |||
| NCT04271475 2019-004131-24 Details | 2024-02-02 Interventional | 3 | 127 | Macitentan Hypertension Hypertension, P… Chronic Thrombo… | The Sponsor decided to stop the study for futility based on a recommendation by the IDMC
following a pre-planned interim analysis - | |||
| NCT03595371 Details | 2024-02-02 Interventional | 2 | 2 | Dapansutrile Schnitzler Synd… Syndrome | The study was terminated due to study design issues that did not allow for determination of
efficacy and safety in subjects with Schnitzler Syndrome who are currently well controlled on
anakinra therapy. - | |||
| NCT02654587 2015-003183-36 Details | 2024-02-02 Interventional | 3 | [1 Refs] | 219 | Docetaxel Pemetrexed Carcinoma, Non-… Lung Neoplasms Non Small Cell … | due to COVID-19 In April 2020 at time of planned interim analysis, decision was taken to prematurely stop the accrual due to COVID-19. Early termination led to small numbers of subject analyzed. The statistical plan was revised to propose the primary efficacy analysis in subgroup of patients with ICI secondary resistance (defined as progression after ICI second line >= to 12 weeks from stratification criteria based on biological and clinical rationale). | ||
| NCT00529113 Details | 2024-02-02 Interventional | 1 | 33 | Gemcitabine Pancreatic Neop… Pancreatic Canc… | To pursue other indications - | |||
| NCT05688215 Details | 2024-02-01 Interventional | 1/2 | - | Calcium Calcium, Dietar… Fluorouracil Folic Acid Irinotecan Leucovorin Levoleucovorin Oxaliplatin Quemliclustat Adenocarcinoma Borderline Rese… Locally Advance… | Accrual met - | |||
| NCT04601532 Details | 2024-02-01 Interventional | 4 | 26 | Silver Sulfadia… Sulfadiazine Burns Superficial Par… | Delayed recruitment - | |||
| NCT02133885 Details | 2024-02-01 Interventional | 1/2 | 0 | Minocycline Hypertension | This study was never started and no participants were enrolled. - | |||
| NCT01186328 Details | 2024-02-01 Interventional | 1 | [1 Refs] | 6 | Asparaginase Cortisone Cytarabine Doxorubicin Hydrocortisone Hydrocortisone … Hydrocortisone … Hydrocortisone … Methotrexate Pegaspargase Prednisone Vincristine Acute Disease Leukemia Leukemia, Lymph… Precursor Cell … Precursor T-Cel… Leukemia, Lymph… Leukemia, Lymph… Lymphoblastic L… Lymphoblastic L… | Enzon Pharmaceuticals decided to end its development of EZN-3042. The study was terminated early because Enzon Pharmaceuticals decided to halt development of EZN-3042. | ||
| NCT05107856 Details | 2024-01-31 Interventional | 1 | 21 | Azacitidine Venetoclax Leukemia Leukemia, Lymph… Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Lymphoma Lymphoma, B-Cel… Lymphoma, B-Cel… Lymphoma, Folli… Lymphoma, Mantl… Lymphoma, Non-H… Myelodysplastic… Myeloproliferat… Neoplasms Preleukemia Acute Myeloid L… B-cell Non-Hodg… Chronic Lymphoc… Chronic Myelomo… Follicular Lymp… Mantle Cell Lym… Marginal Zone L… Myeloproliferat… Small Lymphocyt… | Company Decision - | |||
| NCT04990804 Details | 2024-01-31 Interventional | 4 | 8 | Analgesics Analgesics, Opi… Spinal Diseases Opioid Use Postoperative P… Surgery Surgery--Compli… | Limitations of the prospective study design revealed that a retrospective study design would be
better suited. - | |||
| NCT04860635 Details | 2024-01-31 Interventional | 2/3 | - | Celecoxib Analgesia | Study superseded by alternative Phase 3 trial - | |||
| NCT04564417 2019-002299-15 Details | 2024-01-31 Interventional | 1 | 33 | Pembrolizumab Neoplasms Locally Advance… | - - | |||
| NCT03152409 Details | 2024-01-31 Interventional | 2 | 32 | Aspirin Salicylates Salicylic Acid Depression Depressive Diso… Depressive Diso… Depressive Diso… Major Depressiv… Treatment Resis… | Inadequate resources to complete the study In Mar. 2020 study placed on prolonged pause due to the pandemic. Research activities resumed with limitations later that year. The last study participant was screened in Feb. 2021. However, personnel departure affected study activities, so study was again paused, with plans to resume once adequate personnel were hired. However no additional support was provided. In Dec. 2022, it was decided to terminate the study when it became clear that resources would be insufficient to complete the trial. | |||
| NCT05435235 Details | 2024-01-30 Interventional | 4 | - | Dapagliflozin Acute Kidney In… Wounds and Inju… Percutaneous Co… | Laboratory UNGAL - | |||
| NCT05192213 Details | 2024-01-30 Interventional | 3 | 71 | Hydrocortisone Thiamine Shock Shock, Septic Sepsis Septic Shock | In order to preserve the safety of the patients and prevent any harm from occurring, we opted
to discontinue the study based on previous results (LOVIT study) published at 2022. Were
recruited 71 than 1090 participants. - | |||
| NCT04925986 Details | 2024-01-30 Interventional | 2 | 9 | Pembrolizumab Carcinoma Carcinoma, Non-… Lung Diseases Lung Neoplasms Advanced Treatm… Metastatic Lung… PD-L1 Gene Muta… Pembrolizumab Sitravatinib Stage IV Lung N… | Sponsor decision based on data from other clinical trials - | |||
| NCT04609579 Details | 2024-01-30 Interventional | 1 | 27 | Pembrolizumab Lymphoma Advanced Lympho… Advanced Solid … | Sponsor decision (not due to safety concerns) - |